Health Robotics Announces Partnership in the People's Republic of China With The Devon Internati... (t several key Chinese healthcare officia...)

Health Robotics Announces Partnership in the People's Republic of China With The Devon International Group

Date:12/29/2008

t several key Chinese healthcare officials and hospitals in October 2008, I became convinced that China is ready to begin embracing Health Robotics' solutions in the critical area of cancer care where medication errors can mean the difference between life and death. While CytoCare(TM) remedies the considerable Chinese-specific problem of retention of child-bearing-age clinicians due to the hazardous nature of Chemo IVs, i.v.STATION(TM) solves the IV sterility issues associated with compounding at non-sterile patient care locations. We look forward to officially launch both Health Robotics' solutions at the China International Medical Equipment Fair in Shenzhen on April 18-21, 2009," stated John A. Bennett, CEO of the Devon International Group.

"We are very pleased to expand our strategic DIG partnership with comprehensive operations in China, including the potential to streamline costs and manufacturing operations by utilizing DIG's competitive advantages with access to its world-class, ISO-certified, China-based high-tech and medical devices manufacturing expertise. In addition we are excited to work with the 40-people-strong DIG marketing and service teams in Shanghai and Beijing. This rounds up an excellent year for our company where we have continued to see the exclusive worldwide dominance of CytoCare(TM).

This global dominance has been further proven recently by Jane Arnot, a senior VP from one of our potential competitors, mailing several CytoCare(TM) "live" customers to request visits by RIVA's engineering staff in order to attempt to learn how to prepare chemotherapy drugs with robotic technology and learn from CytoCare(TM) features.

These requests from Ms. Arnot came more than three years after the same company (IHS) publicly announced that they were already able to handle chemotherapy IV medications, and curiously, also subsequent to the fact that the same company was unable to deliver on-t
'/>"/>

1

GOOD

Page: 1 2 3 4
Related biology technology :

1. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
2. Research Triangle Area Health Care Collaborative Launches Bridges to Excellence(R) Initiative to Improve Quality and Lower Costs
3. Healthcare Technologies Calls for a Shareholders Meeting to Approve the Nexgen Biofuels Transaction
4. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
5. Ohio Ranks Best in the Midwest for Venture Capital Investment in Health Care Bioscience Industry
6. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
7. InterCure and Omron Healthcare (UK) Ltd. Announce Marketing Collaboration for Hypertension Market in United Kingdom
8. Apria Healthcare Chooses Masimo SET Pulse Oximetry for Use in the Companys Home Health Care Business
9. NuVasive to Present at Thomas Weisel Partners Healthcare Conference
10. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
11. Boston Scientific to Participate in the Bear Stearns 20th Annual Healthcare Conference

Post Your Comments:

Health Robotics Announces Partnership in the People's Republic of China With The Devon Internati...(t several key Chinese healthcare officia...)